周二，受分析师积极情绪和一家知名投资公司大规模收购的推动， CRISPR Therapeutics AG 夜盘股价走高。投资者对多份分析师报告和一笔大规模股票收购做出反应，这家基因编辑公司的股价上涨势头强劲。
Chardan Capital 引领乐观情绪，重申其对 CRISPR Therapeutics 的“买入”评级，目标价为 82.00 美元，表明其股价仍有巨大的上涨潜力。巴克莱和 RBC Capital 维持“持有”评级，但其目标价分别为 56.00 美元和 42.00 美元，表明其股价较当前水平仍有上涨空间。这些评级，尤其是 Chardan Capital 的看涨预期，似乎增强了投资者对该公司前景的信心。
Cathie Wood 的 ARK Investment 采取了重大举措，增持了 181,300 股 CRISPR Therapeutics 股票，为股价上涨增添了动力。这项由一家以专注于创新和颠覆性技术而闻名的知名投资公司进行的大规模收购，很可能是对该公司未来发展的强烈信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
